Skip to content
Tech News
← Back to articles

Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion

2026-03-31 | original
read original get Biogen Apellis Collaboration Kit → more articles

The deal will expand Biogen’s portfolio in immunology and rare-disease medicines.

Explore topics: biogen apellis pharmaceuticals immunology rare diseases acquisition
Related:
Novartis to Buy Allergy-Drug Developer Excellergy for Up to $2 Billion
Novartis to Buy Biotech Excellergy for Up to $2 Billion
Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion
The Entrepreneur’s Strategic Guide to Buying a Business
Elon Musk misled Twitter investors while trying to get out of acquisition, jury says

© 2026 GoKawiil

About | Editorial Policy | Contact